X Pivot1, J P Spano2, M Espie3, P Cottu4, C Jouannaud5, V Pottier6, L Moreau7, J M Extra8, A Lortholary9, P Rivera10, D Spaeth11, H Attar-Rabia12, C Benkanoun12, L Dima-Martinez12, N Esposito12, J Gligorov13. 1. University Hospital Jean Minjoz, INSERM 1098, Besancon, France. Electronic address: xavier.pivot@univ-fcomte.fr. 2. AP-HP Pitié-Salpêtrière-Charles Foix, UPMC Université Paris 06, Paris, France. 3. Hôpital Saint Louis, AP-HP, Paris, France. 4. Institut Curie, Paris, France. 5. Institut Jean Godinot, Reims, France. 6. Centre Leonard De Vinci, Dechy, France. 7. Pôle Santé République - Clinique Clermont-Ferrand, Clermont Ferrand, France. 8. Institut Paoli-Calmettes, Marseille, France. 9. Centre Catherine de Sienne, Nantes, France. 10. Institut Claudius-Regaud, Toulouse, France. 11. Gentilly Oncology Centre, Nancy, France. 12. Roche, Boulogne-Billancourt, France. 13. APHP Tenon, Inserm U938, IUC-UPMC Sorbonne Université, Paris, France.
Abstract
HannaH (NCT00950300) and PrefHer (NCT01401166) studies validated the subcutaneous (H-s.c.) formulation of trastuzumab as effective and safe as intravenous (H-i.v.) and highly preferred by patients in early breast cancer. The present randomised MetaspHer trial (NCT01810393) is the first study assessing patient's preference in metastatic setting. METHODS:Patients with HER2-positive metastatic breast cancer who completed a first line chemotherapy with trastuzumab and achieved a long-term response lasting more than 3 years were randomised to receive 3 cycles of 600-mg fixed-dose adjuvant H-s.c., followed by 3 cycles of standard H-i.v., or the reverse sequence. Primary end-point was overall preference for H-s.c. or H-i.v. at cycle six, assessed by Patient Preference Questionnaire (PPQ). Secondary end-points included healthcare professional (HCP) satisfaction; safety and tolerability; quality of life. RESULTS:Hundred and thirteen patients were randomised and treated. H-s.c. was preferred by 79/92 evaluable intent-to-treat patients (85.9%, 95% confidence interval [CI; 78.8-93.0]; p < 0.001), 13/92 preferred H-i.v. (14.1%, 95% CI [7.0-21.3]). HCPs were most satisfied with H-s.c. (56/88 available data, 63.6%, [53.6-73.7]). On the safety population, adverse events occurred in 73 (67.6%) and 49 (44.1%) patients during the H-s.c. and H-i.v. periods, respectively; 7 (6.5%) and 4 (3.6%) were grade ≥ III, 3 (2.8%) and 2 (1.8%) were serious. CONCLUSION: The safety was consistent with the known H-i.v. and H-s.c. profiles without safety concern raised. Definitively, patients preferred H-s.c. as reported in early stage by PrefHer study.
RCT Entities:
HannaH (NCT00950300) and PrefHer (NCT01401166) studies validated the subcutaneous (H-s.c.) formulation of trastuzumab as effective and safe as intravenous (H-i.v.) and highly preferred by patients in early breast cancer. The present randomised MetaspHer trial (NCT01810393) is the first study assessing patient's preference in metastatic setting. METHODS:Patients with HER2-positive metastatic breast cancer who completed a first line chemotherapy with trastuzumab and achieved a long-term response lasting more than 3 years were randomised to receive 3 cycles of 600-mg fixed-dose adjuvant H-s.c., followed by 3 cycles of standard H-i.v., or the reverse sequence. Primary end-point was overall preference for H-s.c. or H-i.v. at cycle six, assessed by Patient Preference Questionnaire (PPQ). Secondary end-points included healthcare professional (HCP) satisfaction; safety and tolerability; quality of life. RESULTS: Hundred and thirteen patients were randomised and treated. H-s.c. was preferred by 79/92 evaluable intent-to-treat patients (85.9%, 95% confidence interval [CI; 78.8-93.0]; p < 0.001), 13/92 preferred H-i.v. (14.1%, 95% CI [7.0-21.3]). HCPs were most satisfied with H-s.c. (56/88 available data, 63.6%, [53.6-73.7]). On the safety population, adverse events occurred in 73 (67.6%) and 49 (44.1%) patients during the H-s.c. and H-i.v. periods, respectively; 7 (6.5%) and 4 (3.6%) were grade ≥ III, 3 (2.8%) and 2 (1.8%) were serious. CONCLUSION: The safety was consistent with the known H-i.v. and H-s.c. profiles without safety concern raised. Definitively, patients preferred H-s.c. as reported in early stage by PrefHer study.
Authors: S Dent; C Ammendolea; A Christofides; S Edwards; D Incekol; B Pourmirza; S Kfoury; B Poirier Journal: Curr Oncol Date: 2019-02-01 Impact factor: 3.677
Authors: Sherko Kuemmel; Carlo A Tondini; Jacinta Abraham; Zbigniew Nowecki; Bartosz Itrych; Erika Hitre; Bogusława Karaszewska; Alejandro Juárez-Ramiro; Flavia Morales-Vásquez; Jose Manuel Pérez-García; Servando Cardona-Huerta; Estefania Monturus; Marco Sequi; Eleonora Restuccia; Mark Benyunes; Miguel Martín Journal: Breast Cancer Res Treat Date: 2021-03-21 Impact factor: 4.872
Authors: Hannelore Denys; Corina L Martinez-Mena; Marc T Martens; Randal G D'Hondt; Marie-Pascale L Graas; Ella Evron; Georgeta Fried; Noa E Ben-Baruch; Christof Vulsteke; Mona M Van Steenberghe Journal: Breast Cancer Res Treat Date: 2020-04-02 Impact factor: 4.872